Provided herein are B7-H3 antibodies, fragments of such antibodies, and compositions comprising the same. The antibodies, antibody fragments and compositions are useful in a number of analytical methods, including immunohistochemical and immunocytochemical detection and analysis of B7-H3. Also provided herein are isolated peptides and fusion proteins containing immunogenic determinants for said B7-H3 antibodies, animals immunized with the peptides and fusion proteins, isolated B cells obtained from the animals, and hybridomas made from the isolated B cells.

Diagnostic platforms for the detection of mucinous and high grade cysts in the pancreas of subjects are provided. The disclosure provides a system comprising enzyme specific substrate, that are specific for detection and/or quantification of serine protease TPP-1, the value of which corresponding to a determination of whether a mucinous cyst in the pancreas is malignant or benign. The disclosure also provides for a two-step method, in which a sample from a pancreatic cyst is determined mucinous by detection and/or quantification of aspartyl protease expression, and then the same cyst is determined high grade dysplasia or malignant by detection and/or quantification of serine protease expression.

The present disclosure provides antigen-binding proteins which bind to Claudin-18.2 (CLDN18.2); bispecific antigen-binding proteins which bind to CLDN18.2 and a second antigen; and conjugates thereof. In various aspects, the antigen-binding proteins bind to Extracellular Loop 1 (EL1) of the extracellular domain of CLDN18.2. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.

A system for treating cancer and evaluating chemo-preventive potential of PHC and its prepared chitosan nanoparticles is described. The rats are divided into eight groups, from which group 1 is served as normal control, and group 2-8 are given single dose of DEN and repeated dose of CCl.sub.4, wherein freshly prepared solution of DEN in normal saline is used for the induction of HCC in rats by administering 200 mg/kg, i.p., PHC (2:1:1) in normal saline suspension to administer at doses of 900 mg/kg, wherein serum and tissue samples are collected after anesthetizing overnight fasted rats using intraperitoneal administration of thiopentone sodium at a dose of 40 mg/kg, wherein the collected serum and tissue samples is treated and thereby the chemo-preventive potential of PHC (2:1:1) and its prepared chitosan nanoparticles is evaluated upon determining liver markers, antioxidant parameters, total bilirubin, protein, lipid peroxidation, and liver cancer biomarkers.

This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.

A method, a composition and a kit for screening an ALK or ROS-1 kinase inhibitor are disclosed in the present specification. In an aspect, by the method, composition and kit for screening an ALK or ROS-1 kinase inhibitor according to the present disclosure, it is possible to conduct simultaneous quantitative and qualitative analysis and faster screening of a larger number of candidate substances as compared with conventional molecular biological experimental methods and to grasp the overall level of change in a plurality of different metabolites in a cell line by candidate substances of ALK or ROS-1 kinase inhibitor and thus the screening efficiency for drugs which exert an ALK or ROS-1 kinase inhibitory effect is excellent. Consequently, the present disclosure has an advantage of being able to be used in various ways in the development of new drugs which exert an ALK or ROS-1 kinase inhibitory effect.

Provided herein are methods for the diagnosis, or management of liver diseases, e.g.. hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids.

A marker having excellent sensitivity and specificity to pancreatic cancer and intraductal papillary mucinous neoplasms. Also, a kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms to detect the marker, and a method for evaluating a metastasis of a pancreas cancer cell by using the marker. The marker for pancreatic cancer and intraductal papillary mucinous neoplasms according to the present invention comprises one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein. The kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms according comprises an antibody to one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein.

The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art. The present disclosure also relates to methods of using the specific binding agents to detect the presence of PIVKA-II.

Disclosed herein is a novel compound of formula (I) for detecting circulating cancerous cells, particularly, cholangio-cancerous cells, from a biological sample, ##STR00001##
wherein, R.sub.1 and R.sub.2 are independently H, or —SO.sub.3M; and M is a monovalent cation selected from the group consisting of sodium ion, potassium ion, lithium ion or ammonium ion. Also disclosed herein is a method of treating and detecting cholangio-cancerous cells from a biological sample of a subject suspected of having cholangiocarcinoma (CCA). The method includes steps of, contacting the biological sample with a magnetic bead pre-coated with the compound of formula (I); detecting a complex formed between the magnetic bead and the biological sample in an immunoassay; and administering to the subject an effective amount of a chemotherapeutic agent to ameliorate symptoms associated with the CCA.